Advertisement

Sexualität und Pharmakotherapie

Arzneimittelinduzierte sexuelle Funktionsstörungen und medikamentöse Optionen zur Behandlung sexueller Dysfunktionen
  • Uwe Hartmann
  • C. Rüffer-Hesse
Leitthema: Sexualmedizin

Zusammenfassung

Der vorliegende Beitrag beschäftigt sich mit 2 unterschiedlichen Bereichen der komplexen Zusammenhänge zwischen Pharmakotherapie und sexuellen Funktionen bzw. Dysfunktionen bei Männern und Frauen. Viele Beeinträchtigungen der Sexualität werden auf Medikamentennebenwirkungen zurückgeführt, dabei spielen Psychopharmaka eine wichtige Rolle. Der erste Teil des Beitrages beschreibt daher die Substanzen und pharmakodynamischen Mechanismen, die für Sexualstörungen verantwortlich sein können mit Schwerpunkt auf Antidepressiva und Neuroleptika. Die Abgrenzung medikamentös bedingter Beeinträchtigungen von den unmittelbar der Grunderkrankung zuzuordnenden ist häufig schwierig. Es werden Möglichkeiten des klinischen Umgangs mit den Störungsbildern und deren Abhilfe diskutiert. Im zweiten Teil werden die aktuellen medikamentösen Behandlungsoptionen für sexuelle Dysfunktionen von Männern und Frauen diskutiert. Für Frauen gibt es noch keine zugelassene und bewährte Medikation, abgesehen von transdermalen Testosteronpflastern für ovariektomierte Frauen mit sexueller Appetenzstörung. Für Männer existiert hingegen eine effektive Pharmakotherapie für die Erektionsstörung. Darüber hinaus ist die Testosteronsubstitution die Therapie der Wahl für appetenzgeminderte Männer mit Hypogonadismus. Da sexuelle Funktionsstörungen häufig durch eine Kombination organischer und psychischer Faktoren verursacht sind, wird eine kombinierte pharmakologische und sexualtherapeutische Herangehensweise befürwortet.

Schlüsselwörter

Sexuelle Funktionsstörungen Pharmakotherapie sexuelle Arzneimittelnebenwirkungen medikamenteninduzierte Sexualstörungen 

Sexuality and pharmacotherapy. Medication-induced disorders of sexual response and pharmacotherapeutic options for the treatment of sexual dysfunctions

Abstract

This contribution addresses two different areas of the complex relationship between pharmacotherapy and sexual function and dysfunction in men and women. As many impairments of sexual function are caused by side effects of medications, particularly psychotropic drugs, the first part of the paper describes substances and mechanisms often related to sexual dysfunction with a special focus on antidepressants and neuroleptics. While serotonine-reuptake inhibitors entail a high risk of sexual dysfunction, it is often difficult to differentiate the nega tive impact of the drug from the impairment caused by the mental disorder itself. Ways to deal with these dysfunctions and remedial measures are discussed. In the second section, current pharmacological treatments for female and male sexual dysfunctions are reviewed. While there is no approved pharmacotherapy with established efficacy for female sexual dysfunction with the possible exception of the transdermal testosterone patch for surgically menopausal women, effective pharmacological therapies are available for male erectile disorders. In addition, testoste- rone substitution is the treatment of choice for hypoactive sexual desire disorders caused by hypogonadism. As sexual dysfunctions are often caused by a mixture of psychological and organic factors, treatment strategies combining pharmacological options and sex therapy are advocated.

Keywords

sexual dysfunctions pharmacotherapy sexual side effects medication induced sexual dysfunctions 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Araujo AB, Durante R, Feldman HA (1998) The relationship between depressive symptoms and male erectile dysfunction:cross-sectional results from the Massachussetts Male Aging Study. Psychosomatic Med 60:458–465Google Scholar
  2. 2.
    Thase ME, Howland RH (1995) Biological processes in depression:an updated review and integration. In:Beckham, EE, Leber WR (eds) Handbook of depression, 2nd edn. Guilford Press, New York, pp 213–279Google Scholar
  3. 3.
    Gregorian RS, Golden KA, Bahce A et al. (2002) Antidepressant induced sexual dysfunction. Annals Pharmacother 36:1577–1589CrossRefGoogle Scholar
  4. 4.
    Zajecka J (2001) Strategies for the treatment of antidepressant-related sexual dysfunction. J Clin Psychiatry 62 [Suppl 3]:35–43PubMedGoogle Scholar
  5. 5.
    Balon (1999) Case Report – Sildenafil and sexual dysfunction associated with antidepressants. J Sex Marital Ther 25:259–264PubMedCrossRefGoogle Scholar
  6. 6.
    Nurnberg HG et al. (2000) Sildenafil in the treatment of sexual dysfunction induced by selective serotonin reuptake inhibitors:an overview. CNS Drugs, 13, No. 5:321–335CrossRefGoogle Scholar
  7. 7.
    Rosen R, Shabsigh R, Berber M et al. (2006) Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction:the depression- related improvement with vardenafil for erectile response study. Am J Psychiatry 163:79–87PubMedCrossRefGoogle Scholar
  8. 8.
    Lewis RW, Sadovsky R, Eardley I et al. (2005) The efficacy of tadalafil in clinical populations. J Sex Medicine 2:517–531CrossRefGoogle Scholar
  9. 9.
    Dossenbach M, Hodge A, Anders M et al. (2005) Prevalence of sexual dysfunction in patients with schizophrenia:international variation and underestimation. Int J Neuropsychopharmacol 8:1–7CrossRefGoogle Scholar
  10. 10.
    Weig W (2006) Psychopharmaka und sexuelle Störungen. Blickpunkt Mann 2:19–22Google Scholar
  11. 11.
    Weig W, Cohen S, Kühn KU, Sträter B (in Vorbereitung) Sexualstörungen bei stationär psychiatrisch behandelten Patienten – eine multizentrische PrävalenzstudieGoogle Scholar
  12. 12.
    Perquin L, Steinert T (2004) A review of the efficacy, tolerability and safety of sertindole in clinical trials. CNS Drugs 18 [Suppl 2]:19–30PubMedCrossRefGoogle Scholar
  13. 13.
    Dossenbach M, Dyachkova Y, Pirildar S et al. (2006) Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia:12-month results from the international schizophrenia outpatient health outcomes (ICSOHO) study. Eur Psychiatry 21:251–258PubMedCrossRefGoogle Scholar
  14. 14.
    Kinzel U, Weig W (2004) Medikamente und ihre Nebenwirkungen auf die Sexualität. Psycho Neuro 30:53–56Google Scholar
  15. 15.
    Laumann EO, Nicolosi A, Glasser DB et al. (2005) Sexual problems among women and men aged 40–80 y:prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res 17:39–57PubMedCrossRefGoogle Scholar
  16. 16.
    American Psychiatric Association (2000) Diagnostic Criteria from DSM –IV-TR. American Psychiatric Association, Washington, D.C.Google Scholar
  17. 17.
    Guiliano F, Allard J (2001) Dopamine and sexual function. Int J Impot Res 13 [Suppl 3]:18–28CrossRefGoogle Scholar
  18. 18.
    Nedergaard P (1999) Dopaminergic and serotonergic control of sexual behavior. Scand J Sex 2(1):3–11Google Scholar
  19. 19.
    Caruso S, Agnello C, Intelisano G et al. (2003) Placebo-controlled study on efficacy and safety of daily apomorphine SL intake in premenopausal women affected by hypoactive sexual desire disorder and sexual arousal disorder. Urology 63(5):955–959CrossRefGoogle Scholar
  20. 20.
    Bechara A, Bertolino MV, Casabe A et al. (2004) A double-blind randomized placebo control study comparing the objective and subjective changes in female sexual response using sublingual apomorphine. J Sex Med 1:209–214PubMedCrossRefGoogle Scholar
  21. 21.
    Zimmermann M, Posternak MA et al. (2005) Why isn‘t Bupropion the most frequently prescribed antidepressant? J Clin Psychiatry 66(5):603–610Google Scholar
  22. 22.
    Gardner E, Johnston JA (1985) Bupropion – an antidepressant without sexual pathophysiological action. J Clin Psychopharmacol 5(1):24–29PubMedCrossRefGoogle Scholar
  23. 23.
    Crenshaw TL, Goldberg JP, Stern WC (1987) Pharmacologic modification of psychosexual dysfunction. J Sex Mar Ther 13(4):239–252Google Scholar
  24. 24.
    Segraves RT, Clayton A, Croft H et al. (2004) Bupropion sustained release for the treatment of hypoactive sexual desire disorder. J Clin Psychopharm 24(3):339–342CrossRefGoogle Scholar
  25. 25.
    Segraves RT, Croft H, Kavoussi R et al. (2001) Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women. J Sex Mar Ther 27:303–316CrossRefGoogle Scholar
  26. 26.
    Modell JG, May RS, Katholi CR (2000) Effect of Bupropion-SR on orgasmic dysfunction in nondepressed subjects:a pilot study. J Sex Mar Ther 26:231–240CrossRefGoogle Scholar
  27. 27.
    Gitlin MJ, Suri R, Altshuler L et al. (2002) Bupropion- sustained release as a treatment for SSRIinduced sexual side effects. J Sex Mar Ther 28:131–138CrossRefGoogle Scholar
  28. 28.
    DeBattista C, Solvason B, Poirier J et al. (2005) A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction. J Clin Psychiatry 66(7):844–848PubMedGoogle Scholar
  29. 29.
    Ginzburg R, Wong Y, Fader JS (2005) Effect of Bupropion on sexual function. Ann Pharmacotherapy 39:2096–2099CrossRefGoogle Scholar
  30. 30.
    Bartlik B, Kaplan P, Kaminetsky J et al. (1999) Medications with the potential to enhance sexual responsivity in women. Psychiatric Annals 29:46–52Google Scholar
  31. 31.
    Gartrell N (1986) Increased libido in women receiving trazodone. A J Psychiatry 143:781–782Google Scholar
  32. 32.
    Sullivan G (1988) Increased libido in three men treated with trazodone. J Clin Psychiatry 49(5):202–203PubMedGoogle Scholar
  33. 33.
    Othmer E, Othmer SC (1987) Effect of buspirone on sexual dysfunction in patients with generalized anxiety disorder. J Clin Psychiatry 48:201–203PubMedGoogle Scholar
  34. 34.
    Lauerma H (1995) A case of moclobemide-induced hyperorgasmia. Int Clin Psychopharmacol 10:123–124PubMedCrossRefGoogle Scholar
  35. 35.
    Pfaus JG, Shadiack A, Van Soest T et al. (2004) Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. PNAS 101(27):10201–10204PubMedCrossRefGoogle Scholar
  36. 36.
    Wessels H, Levine N, Hadley ME et al. (2000) Melanocortin receptor agonists, penile erection, and sexual motivation:human studies with Melanotan II. Int J Imp Res 12 [Suppl 4]:74–79CrossRefGoogle Scholar
  37. 37.
    Diamond LE, Earle DC, Heiman JR et al. (2006) An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by Bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med 3:628–638PubMedCrossRefGoogle Scholar
  38. 38.
    Davis S (2000) Testosterone and sexual desire in women. J Sex Educ Ther 25(1):25–32Google Scholar
  39. 39.
    Sarrel PM (1999) Psychosexual effects of menopause:role of androgens. Am J Obstet Gynecol 180:219–224CrossRefGoogle Scholar
  40. 40.
    Shifren JL, Braunstein GD, Simon JA et al. (2004) Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 343(10):682–688CrossRefGoogle Scholar
  41. 41.
    Laughlin GA, Barret-Connor E, Kritz-Silverstein D, von Muhlen D (2000) Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women:the Rancho Bernardo Study. J Clin Endocrinol Metab 85:645–651PubMedCrossRefGoogle Scholar
  42. 42.
    Bancroft J (2002) Sexual effects of androgens in women:some theoretical considerations. Fertil Steril 77 [Suppl 4]:55–59CrossRefGoogle Scholar
  43. 43.
    Nathorst-Boos J, von Schoultz B (1992) Psychological reactions and sexual life after hysterectomy with and without oophorectomy. Gynecol Obstet Invest 34:97–101PubMedCrossRefGoogle Scholar
  44. 44.
    Sherwin BB, Gelfand M (1987) The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 49:397–409PubMedGoogle Scholar
  45. 45.
    Simon J, Braunstein G, Nachtigall L et al. (2005) Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 90(9):5226–5233PubMedCrossRefGoogle Scholar
  46. 46.
    Buster JE, Kingsberg SA, Aguirre O et al. (2005) Testosterone patch for low sexual desire in surgically menopausal women:a randomized trial. Obstetrics Gynecology 105(5/1):944–952PubMedGoogle Scholar
  47. 47.
    Basson R (2006) Sexual desire and arousal disorders in women. N Engl J Med 354(14):1497–1506PubMedCrossRefGoogle Scholar
  48. 48.
    Berman JR, Berman L, Goldstein I (1999) Female sexual dysfunction:incidence, pathophysiology, evaluation, and treatment options. Urology 54:385–391PubMedCrossRefGoogle Scholar
  49. 49.
    Allolio B, Arlt W (2002) DHEA treatment:myth or reality? Trends Endocrinol Metab 13:288–294PubMedCrossRefGoogle Scholar
  50. 50.
    Spark RF (2002) Dehydroepiandrosterone:a springboard hormone for female sexuality. Fertil Steril 77:19–25CrossRefGoogle Scholar
  51. 51.
    Arlt W, Callies F, van Vlijmen JC et al. (1999) Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 341:1013–1020PubMedCrossRefGoogle Scholar
  52. 52.
    Lovas K, Gebre-Medhin G, Trovik TS et al. (2003) Replacement of dehydroepiandrosterone in adrenal failure:no benefit for subjective health status and sexuality in a 9-month, randomized, parallel-group clinical trial. J Clin Endocrinol Metab 88:1112–1118PubMedCrossRefGoogle Scholar
  53. 53.
    Marthol H, Hilz MJ (2004) Weibliche sexuelle Funktionsstörungen:Klassifikation, Diagnostik und Therapie. Fortschr Neurol Psychiat 72:121–135PubMedCrossRefGoogle Scholar
  54. 54.
    Park K, Moreland RB, Goldstein I (1998) Sildenafil inhibits phosphodiesterase Type V in human clitoral corpus cavernosum smooth muscle. Biochem Biophysic Res Com 249:612–617CrossRefGoogle Scholar
  55. 55.
    Caruso S, Intelisano G, Lupo L, Agnello C (2001) Premenopausal women affected by sexual arousal disorder treated with sildenafil:a double-blind, cross-over, placebo-controlled study. B J Obstet Gyn 108:623–628CrossRefGoogle Scholar
  56. 56.
    Basson R, Brotto LA (2003) Sexual psychophysiology and effects of sildenafil citrate in oestrogenised women with acquired genital arousal disorder and impaired orgasm:a randomised controlled trial. BJOG 110:1014–1024PubMedCrossRefGoogle Scholar
  57. 57.
    Basson R, McInnes R, Smith MD et al. (2002) Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal. J Womens Health Gend Based Med 11:367–377PubMedCrossRefGoogle Scholar
  58. 58.
    Berman JR, Berman LA, Lin H et al. (2001) Effect of sildenafil on subjective and physiologic parameters of the female sexual response in women with sexual arousal disorder . J Sex Marital Ther 27:411–420PubMedGoogle Scholar
  59. 59.
    Shen WW, Urosevich Z, Clayton DO (1999) Sildenafil in the treatment of female sexual dysfunction induced by selective serotonin reuptake inhibitors. Journal of Reproducitve Medicine 44(6):535–542Google Scholar
  60. 60.
    Nurnberg HG, Lauriello J, Hensley PL et al. (1999) Sildenafil for iatrogenic serotonergic antidepressant medication-induced sexual dysfunction in 4 patients. J Clin Psychiatry 60(1):33–35PubMedGoogle Scholar
  61. 61.
    Nurnberg HG, Hensley PL, Lauriello J et al. (1999) Sildenafil for women patients with antidepressantinduced sexual dysfunction. Psychiatric Services 50 (8):1076–1078PubMedGoogle Scholar
  62. 62.
    Lightner DJ (2002) Female sexual dysfunction. Mayo Clin Proc 77:698–702PubMedCrossRefGoogle Scholar
  63. 63.
    Rutherford D, Collier A (2005) Sexual dysfunction in women with diabetes mellitus. Gyn Endocrin 21(4):189–192CrossRefGoogle Scholar
  64. 64.
    Caruso S, Rugolo S, Agnello C et al. (2006) Sildenafil improves sexual functioning in premenopausal women with type 1 diabetes who are affected by sexual arousal disorder:a double-blind, crossover, placebo-controlled pilot study. Fertil Steril 85(5):1496–1501PubMedCrossRefGoogle Scholar
  65. 65.
    Rosen RC, Philipps NA, Gendrano NC et al. (1999) Oral phentolamine and female sexual arousal disorder:a pilot study. J Sex Marital Ther 25:137–144PubMedCrossRefGoogle Scholar
  66. 66.
    Meston CM, Worcel M (2002) The effects of yohimbine plus l-arginine glutamate on Sexual arousal in postmenopausal women with sexual arousal disorder. Arch Sex Beh 31(4):323–332CrossRefGoogle Scholar
  67. 67.
    Waldinger MD (2003) Rapid ejaculation. In:Levine SB, Risen CB, Althof SE (eds) Handbook of clinical sexuality for mental health professionals. Brunner- Routledge, New York, pp 257–274Google Scholar
  68. 68.
    Porst H (2000) Manual der Impotenz. Uni-Med, BremenGoogle Scholar
  69. 69.
    Sperling H, Hartmann U, Weidner W, Stief CG (2005) Erektile Dysfunktion:Pathophysiologie, Diagnostik und Therapie. Dtsch Ärztebl 102:A1664–1669Google Scholar
  70. 70.
    Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F (2001) Incidence of sexual dysfunction associated with antidepressant agents:a prospective multicenter study of 1022 outpatients. J Clin Psychiatry 62 [Suppl 3]:10–21PubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2006

Authors and Affiliations

  1. 1.Medizinische HochschuleHannoverBRD
  2. 2.Arbeitsbereich Klinische Psychologie, Abt. Klinische Psychiatrie und PsychotherapieMedizinische Hochschule HannoverHannoverBRD

Personalised recommendations